Literatur: Apixaban

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

Apixaban

  • 1. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lassen MR, Raskob GE, Pineo G, Chen D, Hornick P an the ADVANCE-2 investigators. Lancet 2010; 375: 807-815 [PubMed 20206776]
  • 2. Christopher B. Granger, M.D., John H. Alexander, M.D., M.H.S., John J.V. McMurray, M.D., et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365:981-992 [PubMed 1107039]
  • 3. Alexander JH, Lopes RD, James S, et al, "Apixaban with Antiplatelet Therapy After Acute Coronary Syndrome," N Engl J Med, 2011, 365(8):699-708. [PubMed 21780946]
  • 4. Bates SM, Greer IA, Middeldorp S, et al. "VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines," Chest, 2012, 141(2 Suppl):e691-736. [PubMed 22315276]
  • 5. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al, "Apixaban Versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients," N Engl J Med, 2011, 365(23):2167-77. [PubMed 22077144]
  • 6.Lassen MR, Gallus A, Raskob GE, et al, "Apixaban Versus Enoxaparin for Thromboprophylaxis After Hip Replacement," N Engl J Med, 2010, 363(26):2487-98. [PubMed 21175312]
  • 7. Lassen MR, Raskob GE, Gallus A, et al, "Apixaban or Enoxaparin for Thromboprophylaxis After Knee Replacement," N Engl J Med, 2009, 361(6):594-604; published erratum appears in N Engl J Med, 2009, 361(18):1814. [PubMed 19657123]
  • 8. Lassen MR, Raskob GE, Gallus A, et al, "Apixaban Versus Enoxaparin for Thromboprophylaxis After Knee Replacement (ADVANCE-2): A Randomised Double-Blind Trial," Lancet, 2010, 375(9717):807-15. [PubMed 20206776]

 

  top |

 

 
© 2018 Prof. Dr. J. Braun